Last reviewed · How we verify
XOMA 985
XOMA 985 is a monoclonal antibody that targets and inhibits IL-15, a key cytokine involved in immune cell activation and proliferation.
XOMA 985 is a monoclonal antibody that targets and inhibits IL-15, a key cytokine involved in immune cell activation and proliferation. Used for Inflammatory bowel disease (IBD).
At a glance
| Generic name | XOMA 985 |
|---|---|
| Sponsor | Symplmed Pharmaceuticals LLC |
| Drug class | IL-15 inhibitor monoclonal antibody |
| Target | IL-15 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-15 is a critical driver of natural killer (NK) cell and T-cell expansion and survival. By neutralizing IL-15, XOMA 985 modulates immune responses in conditions where excessive or dysregulated immune activation contributes to pathology. This mechanism is being explored in inflammatory and autoimmune conditions where IL-15 plays a pathogenic role.
Approved indications
- Inflammatory bowel disease (IBD)
Common side effects
- Infection
- Infusion-related reactions
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XOMA 985 CI brief — competitive landscape report
- XOMA 985 updates RSS · CI watch RSS
- Symplmed Pharmaceuticals LLC portfolio CI